More Than Words
WORD FERRET IS 100% LLM-FREE
Now Pharma
Rare Disease CRO
Home About us Services News Contact
Personal message for John Smith of Sponsor Pharma
Audio-only track
Hi, John.
I've worked in the rare disease space for years and have been following Sponsor Pharma's successes, most notably the recent OP-101 Phase II study for porphyria.
​
Now Pharma is a specialist CRO in rare disease clinical trials, including porphyria studies. With the announcement of the planned OP-101 Phase III study, now may be a good time to connect. Our porphyria trial experience has shown that in addition to a well-designed protocol, dynamic supply management, a patient-centric approach, and strong analysis tools and methodologies, the CRO's level of relevant experience in this therapeutic area is critical.
​
Would you be open to having an introduction call? I could share insights that may be helpful for you. My calendar is here if you'd like to compare schedules.
Kind regards,
Ray
Ray Collia
Director of Relationship Development
​
Now Phrama Rare Disease CRO
Direct Dial +44 1234 123456
Email contact@nowpharma.com
Now Pharma
Rare Disease CRO
Resources for John Smith
Porphyria Clinical Trial Case Study
Download
Overcoming Challenges in Rare Disease Studies
Read the white paper
Increasing Patient Retention
Read the blog
A Little About Now Pharma
Porphyria
Porphyrias are a group of rare metabolic diseases. They can present in childhood or adult life.
Porphyrias are a group of eight inherited genetic disorders that differ significantly from each other. What is common in all Porphyrias is the accumulation in the body of porphyrins or porphyrin precursors which, although common in the body, normally do not accumulate.
Commonly, Porphyrias are “acute” or “cutaneous”, depending on the primary symptoms.
Research and Development
Now Pharma is a full-service specialist CRO with over 20 years experience in rare diseases clinical trials. Porphyria is one of the specialist areas that we have extensive experience in, including phase I, II, and III adaptive studies.
We understand the particular needs of porphyria patients in clinical trials.
The nuances of these studies impact protocol design, adaptive studies, patient recruitment and retention, and decentralized trials. We can share our experience with you.
Now Pharma
Rare Disease CRO